The new information on Patient #5 is great, but th

The new information on Patient #5 is great, but these PRs are getting long and wordy. Heck, even the title is too long and needs to be more to the point. “CYDY reports continued remarkable results from the 5th patient recently enrolled in the mTNBC trial,” or, “CYDY reports zero CTCs on the 5th patient in the mTNBC trial after only three weeks of treatment.” That’s better.

The information on the 5th patient, the newest patient, should be upfront with comments from Dr. Patterson and NP directly after. That is what new investors and investors on the wall want and need to know, but the impact of that update gets lost in a rambling PR. Updates on the other patients can follow or be left out completely for a separate PR.

And the title discusses the solid tumor trial, but then It’s not discussed in the body of the PR. Leave that out of the title so the newest results from patient #5 is the focus. NP has already discussed enrollment of the solid tumor trial so just leave it out of the PR.

Red Chip continues to underperform in the investor relations realm although I believe NP largely writes these PRs as they read similarly to his interviews.